CDH2 and endometrial cancer: In conclusion, our results reveal that the potential role of a GHRH antagonist in inhibiting human endometrial cancer cell migration and invasion is through the binding of GHRH-R, and the subsequent down-regulation the expression of the metastasis-related proteins Twist and N-cadherin.